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The purpose of this article is to review and update the lit-
erature on the neurobiology of depression considering
both human and animal studies. This review cannot
cover all areas of neurobiology of the illness. Instead, we
will provide some key background on the symptoms,
epidemiology, and neurotransmitter abnormalities in
depression and review the related animal models. A sep-
arate section on studies of sleep electrophysiology
(EEG) in both those with depression and animal models
is included, as this area has provided some of the most
compelling data on the neurobiology of depression.
Finally, we will outline future directions for an integrat-
ed study of the neurobiology of depression. The first
step in such an endeavor requires a review of the diag-
nostic features and symptoms of depression.
Diagnosis
According to the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) (APA 1994), major depres-
sive disorder (MDD) is characterized by one or more
episodes with five or more of the following symptoms
most of the day, nearly every day for at least 2 weeks: 1)
depressed mood; 2) markedly diminished interest or
pleasure in most activities; 3) significant weight loss or
weight gain; 4) insomnia or hypersomnia psychomotor
agitation or retardation; 5) fatigue or loss of energy, feel-
ings of worthlessness, diminished ability to think or con-
centrate; and 6) recurrent thoughts of death. See Table 1
for a summary.
In addition, the symptoms must cause clinically sig-
nificant occupational or social impairment, cannot be
due to a general medical condition (e.g., hypothy-
roidism) or substance or due to bereavement unless per-
sistent beyond 2 months but cannot be mania. The
episode can be further specified as mild, moderate, or
severe; with or without psychotic features; in full or par-
tial remission; chronic (at least 2 years in duration); with
catatonic, melancholic, or atypical features; or with
postpartum onset. Seasonal variation and interepisode
recovery may also be specified. To be considered a
recurrent illness, two or more episodes separated by at
least 2 consecutive months below symptom criteria must
be evident.
Epidemiology
With regard to epidemiology, the lifetime prevalence of
the illness is 6% to 10% and begins most commonly in
the 20s and 30s (Depression Guideline Panel 1993).
Risk factors for depression include prior episodes of the
illness, family history of MDD, prior suicide attempts,
lack of social support, medical comorbidity, stressful life
events, current substance abuse, and female gender.
Women are at twice the lifetime risk as men, beginning
in puberty and continuing to menopause. In addition, the
postpartum period increases the risk of first onset of the
illness and a recurrence in those already ill (Depression
Guideline Panel 1993).
The degree of treatment response is more complicat-
ed to estimate, as it depends on the adequacy of the
diagnosis, choice, and duration of the treatment.
Nevertheless, response rates in a typical 6- to 8-week
trial are estimated at 30% to 60%. It appears that
response rates to newer antidepressants such as sero-
tonin reuptake inhibitors (SRIs) are on par with older tri-
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cyclic medications, although the side effect profiles of
newer agents are more favorable (Depression Guideline
Panel 1993). One exception is that those with atypical
features (weight gain, hypersomnia, reactive mood) are
more likely to respond to monoamine oxidase inhibitors
(MAOIs) or SRIs than to tricyclic antidepressants
(TCAs). Beyond this, response rates seem to be more
determined by dose and length of treatment than by class
of antidepressant per se. These data are of particular
importance when considering the neurotransmitter
abnormalities associated with depression. Both the data
on drug response and the symptoms of depression can be
defined operationally and modeled in the laboratory.
Figure 1 presents a schematic of neurotransmitter abnor-




The observation that pharmacological manipulation of
monoamine-influenced depressive symptoms led to the
hypothesis that depression results from reduced avail-
ability or functional deficiency of serotonin or norepi-
nephrine (Bunney and Davis 1965; Schildkraut 1965;
Schildkraut and others 1968). This view was supported
by the pharmacological action of both TCAs and
MAOIs, namely, the resultant increase in synaptic levels
of monoamines. However, studies of cerebrospinal fluid
could not confirm decreased monoamine metabolites in
those with MDD. Moreover, preclinical studies suggest-
ed that the mechanism of action of antidepressant drugs
was related to changes in monoamine receptor sensitivi-
ty (Charney and others 1981). In a series of more recent
studies, Delgado and colleagues manipulated
monoaminergic function through the ingestion of a tryp-
tophan-free amino acid drink to deplete serotonin and
alpha methyl paratyrosine (AMPT) to deplete cate-
cholamines (Heninger and others 1996). These studies
have shown that although depletion of monoamines does
not increase depressive symptoms, it does induce relapse
in those who have responded to treatment. However, the
effects are specific to the type of antidepressant that pro-
duced the initial clinical response. Patients who respond-
ed to an SRI relapsed with tryptophan depletion. Patients
who responded to imipramine relapsed after AMPT but
not with tryptophan depletion. These data do support
abnormalities in monaminergic sensitivity but suggest
that antidepressant response involves more than just
monoamines.
Increased Cholinergic Sensitivity
Janowsky and colleagues have suggested that the regula-
tion of acetylcholine plays a major role in MDD
(Janowsky and others 1972). Cholinergic agonists,
cholinesterase inhibitors, and acetylcholine precursors
have all been shown to worsen mood in MDD (Janowsky
and others 1983; Dube 1993). Moreover, depressed
patients show a heightened response to muscarinic
cholinergic agonists as evidenced by worsening of mood,
anergia, pupillary constriction, sleep (see Section E),
and beta-endorphin release (Janowsky and others 1972;
Dilsaver and Coffman 1989). Furthermore, abnormali-
ties in levels of cortical choline, an acetylcholine pre-
cursor, have been reported in several brain imaging stud-
ies (Charles and others 1994; Renshaw and others 1994;
Steingard and others 2000). It should be noted, however,
that the increased levels of choline may be localized in
the frontal cortex with decreased levels of choline evi-
dent in other brain regions (Ende and others 1997;
Renshaw and others 1997).
Aminergic/Cholinergic Imbalance
The original Janowsky and others (1972) hypothesis did
not suggest that the underlying neurotransmitter abnor-
mality was exclusively cholinergic. They suggested
instead that an imbalance in cholinergic/noradrenergic
Table 1. Criteria for a Major Depressive Episode (DSM-IV)
Five or more of the following symptoms have been
present during the same 2-week period and repre-
sent a change from previous functioning; at least
one of the symptoms is either 1) depressed mood or
2) loss of interest or pleasure.
1. Depressed mood most of the day, nearly every day,
as indicated by either subjective report (e.g., feels
sad or empty) or observation made by others (e.g.,
appears tearful). In children and adolescents, it can
be irritable mood.
2. Markedly diminished interest or pleasure in all, or
almost all, activities most of the day, nearly every
day (as indicated by either subjective account or
observation made by others).
3. Significant weight loss when not dieting or weight
gain (e.g., a change of more than 5% of body
weight in a month), or decrease or increase in
appetite nearly every day. In children, consider fail-
ure to make expected weight gain.
4. Insomnia or hypersomnia nearly every day.
5. Psychomotor agitation or retardation nearly every
day (observable by others, not merely subjective
feelings of restlessness or being slowed down).
6. Fatigue or loss of energy nearly every day.
7. Feelings of worthlessness or excessive or inappro-
priate guilt (which may be delusional) nearly every
day (not merely self-reproach or guilt about being
sick).
8. Diminished ability to think or concentrate, or indeci-
siveness, nearly every day (either by subjective
account or as observed by others).
9. Recurrent thoughts of death (not just fear of dying),
recurrent suicidal ideation without a specific plan,
or a suicide attempt or a specific plan for commit-
ting suicide.
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neurotransmission characterized those with MDD.
Inherent in this view is the assumption that no single
neurotransmitter abnormality underlies MDD, a position
that has become more appealing (Siever and Davis
1985). As will be explicated below, this view of neuro-
transmitter dysregulation in MDD provides a better fit
with physiological, behavioral, and neurobiological data
in both humans and animals. Figure 2 presents a
schematic of monoaminergic and cholinergic synaptic
action as a guideline for reviewing the animal studies.
With this information in mind, we will now turn to a
review of the animal models of MDD.
Animal Models of MDD
At least 18 distinct animal models of MDD have
appeared in the literature (Yadid and others 2000). A
problem arises when attempting to validate any of these
against MDD. However, Willner (1985) offered an
approach for the evaluation of animal models of depres-
sion on the basis of how well they satisfy three distinct
validity criteria. These criteria are 1) face validity—the
degree to which the model exhibits characteristics that
parallel the human condition; 2) construct validity—the
degree to which derivation of the model parallels our
understanding of the etiology of MDD in humans; and 3)
predictive validity—the degree to which the response of
the animal to antidepressant parallels response in those
with MDD. Many studies have been directed at assessing
and validating the different models of depression, and
this research has been extensively reviewed elsewhere
(for example, see Willner 1997; Nemeroff 1998; Yadid
and others 2000). The current review focuses on animal
models that have reported construct, predictive, and face
validity. Table 2 presents a summary of key animal mod-
els of depression and evidence of validity.
Of the animal models of human depression consid-
ered here, most involve a stressor presented at a point in
the animal’s life that some time later provokes depres-
sive-like behavior in adulthood. This work is a logical
extension of the view that depression arises from a trau-
matic or stressful life event, and thus these models pos-
sess both construct and face validity, in addition to pre-
dictive validity. The models considered in this section




















Fig. 1. Putative neurotransmitter abnormalities in depression,
implicated brain regions, and neurophysiological action.
1. Reciprocal activity of NE and Ach favors Ach in depression
causing short REM latency and negative mood.
2. Low levels of serotonin or lack of sensitivity in serotonin
receptors linked to depression.
3. Stress activates locus coereleus and hypothalamic-pitu-
itary-adrenal (HPA) causing release of norepinephrine and
ultimately depletion of NE.
4. Serotonin and NE activity modulate activity of the nucleus
raphe, which in turn alters release of sex steroids possibly
a contributing factor in observed sex differences in
depression.
5. Animals developing learned helplessness show in increase
in GABA receptors, which may then generate a cascade of
noradrenergic activity through the LC.
6. Reduction of dopamine activation of neurons in the nucle-
us acumbens is related to the appearance of anhedonic
behavior.
Fig. 2. Schematic representation of (A) aminergic and (B)
cholinergic synaptic mechanisms thought to be involved in anti-
depressant efficacy.
• Synthesis (1): Inhibition of 5-HT synthesis in drug-remit-
ted depressed patients causes relapse.
• Release (2): Reduced 5-HT release associated with
depressive symptoms. Effects of monoamine oxide
inhibitors (MAOIs) on depressive symptoms suggest that
excessive degradation of intracellular 5-HT may lead to
reduced 5-HT release.
• Reuptake (3): Presynaptic mechanisms terminate 5-HT
synaptic action. Classic tricyclic antidepressants may have
their effects through inhibition of this uptake mechanism.
• Receptor effects (4): Postsynaptic receptor sensitivity
up-regulation at aminergic sites by tricyclics and electro-
convulsive shocks, and putative super-sensitivity at
cholinergic synapses implicate these mechanisms in
depression.
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model, 3) social defeat, and 4) maternal separation.
Models related to sleep deprivation and regulation are
reviewed later. The first three models can be considered
variants on an adult model of uncontrollable stress, such
Table 2. Summary of Key Animal Models of Depression and Evidence of Validity
Features of Face Validity 
Model Construct Validity (MDD-like Attributes) Predictive Validity References
Chronic mild stress A variety of stressors Reduced consumption Nearly all clinically Willner (1997), Willner
over an extended sweetened solution: effective antidepres- and others (1987, 
period of time lead- anhedonia, ↓ loco- sants tested reverse 1992), Monleon and
ing to reduced he- motor activity, dis- the anhedonia others (1995)
donia A variation on rupted sleep. Re-
learned helplessness versed by several 
days antidepressants
Social defeat Reduced social status, Reduced activity in Reversed by sleep Meerlow, De Boer, 
loss of rank, stress- open field, classic deprivation and others (1996); 
ors that are thought stress response Meerlo, Overkamp,
to lead to depres- Benning, and others
sive behavior (1996); Meerlo, 
Overkamp, Daan, 
and others (1996); 
Meerlo, Overkamp, 
and others (1997); 
Meerlo, Pragt, and 
others (1997);
Meerlo, Van den 
Hoofdakker, and 
others (1997)
Maternal separation Early-life maternal Heightened fear and Several different Chamove and others  
bond affects devel- aggression, inability classes of anti (1973), Heim and 
opment of later to cope with stress, depressant drugs others (1997), Ladd 
emotional life novelty-induced attenuate or reverse and others (1996, 
fearfulness, behavioral and 2000), Liu and 
↑ hypothalamic- endocrinological others (1997)
pituitary-adrenal (HPA) effects of maternal 
response to stressors separation
Early REMS depri- Early-life stressor Sexual response, Behavioral abnormal- Corner and others
vation: drugs leading to depressive- aggression in males, ities respond posi- (1980), Mirmiran 
like behavior reward-seeking, in- tively to imipramine (1986); Mirmiran 
creased REMS, in- treatment and others (1981, 
creased activity in 1983); Vogel and 
outer areas of open others (1980); Vogel, 
field Neill, Hagler, and 
others (1990), Vogel,
Neill, Kors, and 
others (1990)
Early REMS Early-life stressor Anhedonia, reduced ? See this review
deprivation: instru- leading to depressive- intake of sweetened 
mental techniques like behavior solution
Flinders sensitive Genetic predisposition Supersensitive to Chronic treatment Overstreet (1986, 
line of rats for supersensitivity cholinergic agonists, with TCAs, SRIs 1993), Overstreet 
to cholinergic increased REMS, (but not other drugs), and others (1994, 
agonists appetite, and weight, reverse immobility in 1995), Overstreet 
reduced activity forced swim test and Russell (1982), 
(especially in forced Russell and others 
swim test) (1982), Yadid and 
others (2000)
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as an aversive or stressful environmental variable, that
evokes a relatively prolonged reactive “depressive”
response and elicits behaviors consistent with those
observed in patients with MDD. The maternal separation
model crosses over two views of depression that early
traumatic events produce “depressive” behaviors in
adulthood and that there are critical periods in social and
brain development in which the animal (or human) is
particularly vulnerable to long-term consequences of
trauma and stress.
Learned Helplessness
The learned helplessness model of MDD rests on the
premise that animals exposed to uncontrolled or unpre-
dictably aversive events for a sufficient period of time
will develop long-lasting deficits in escape performance
(Miller and Seligman 1975). Early work on learned help-
lessness suggested that during inescapable shock the ani-
mal could not respond behaviorally and thus the only
available response was an alteration in neurotransmitter
activity that in turn produced the depressive behavior
(Anisman and Zacharko 1982). Furthermore, the behav-
ioral responses parallel some of the symptoms of
depression in humans (lack of self-efficacy, hopeless-
ness) (Willner 1984, 1997). Learned helpless animals
also exhibit loss of appetite and weight (Seligman and
others 1980), have decreased locomotor activity
(Wagner and others 1977), and perform poorly in appet-
itively and aversively motivated tasks (Rosellini and oth-
ers 1982, 1984) and in uncontrollable stress paradigms
(Willner 1984). Additionally, TCAs, MAOIs, and elec-
troconvulsive shock effectively reduce the behavioral
and physiological effects of shock exposure, providing
evidence of the face validity of the model (Willner
1984).
Naruo and others (1993) used an unpredictable shock
situation combined with variable ratio response testing
to induce depressive behavior in a set of rats. Animals
exposed to the unpredictable shocks showed a reduction
in the number of successful escapes and were then treat-
ed with either imipramine or chlordiazepoxide. The ani-
mals treated with imipramine showed increases in the
number of successful escapes during testing, whereas
the animals receiving chlordiazepoxide increased their
responding, but not successful responding.
Edwards and others (1992) used the learned helpless-
ness model to evaluate changes in 5-HT. Rats were
exposed to uncontrollable shock and then retrained in a
shock escape task. They found elevated levels of 5-HT in
hippocampal slices of the learned helpless rats but not in
controls, who performed poorly. No group differences
were found in acetylcholine, dopamine, or noradrena-
line. These data suggest that the development of depres-
sion in this animal model is dependent upon increased
levels of 5-HT, but depression in humans has been asso-
ciated with lowered levels of 5-HT that is treated with
SRIs. Petty and others (1994) found similar changes in
5-HT in the medial frontal cortex, using a learned help-
lessness paradigm. They found that 5-HT release after
stress showed a significant increase with helpless behav-
ior.
Work by Wu and others (1999) also examined the role
of serotonin in learned helplessness. No differences were
evident in 5-HT1A receptor density. Moreover, 5-HT2A
receptor density was reduced in the dorsal hippocampus
in the nonhelpless animals. By contrast, 5-HT2A recep-
tor density was reduced in the amygdala in both helpless
and nonhelpless animals. Such results underscore the
complexity in the physiology of learned helplessness. To
further explore the role of 5-HT in learned helplessness,
Papolos and others (1996) antagonized 5-HT2A recep-
tors with an antisense oligonucleotide. This procedure
has the effect of down-regulating activity at these recep-
tors. When compared with controls in a shock avoidance
procedure, the experimental animals behaved as if they
had developed learned helplessness, supporting a reduc-
tion in 5-HT2A activity.
Weiss and Simpson (1988) looked specifically at nor-
epinephrine (NE) changes in the locus coeruleus (LC)
associated with “stress induced depression.” Initially
they found a large depletion of NE in that area following
the induction of stress. Because of this depletion of NE,
it was suggested that this would also reduce activity in
alpha-2 receptors, which normally inhibit firing in LC
neurons. Pharmacological blockade of these neurons
increases the firing of LC neurons to excitatory stimuli.
When the stressed animals were tested with excitatory
stimuli, they also showed an elevation of LC activity,
suggesting diminished activation of alpha-2 receptors.
The overall effect of this transformation in LC would be
to disinhibit LC neurons, resulting in a depletion of NE
in the stressed animals. This is consistent with clinical
findings that drugs that augment NE activity (e.g.,
MAOIs, TCAs) have a beneficial effect on depressed
mood patients. However, Brannan and others (1995) did
not obtain changes in beta adrenergic receptor density
using tail shock stress and shuttle avoidance, indicating
that the development of learned helplessness is depend-
ent upon the specific experimental procedures.
Extending beyond the influence of noradrenergic
transmitter changes, Kram and others (2000) examined
GABAA and GABAB receptor changes in a learned help-
lessness paradigm. They found that helpless animals had
an increase in density of GABAA receptors, whereas ani-
mals that did not develop helplessness showed lower lev-
els of GABAB receptors.
Chronic Mild Stress
Willner (Willner 1997; Willner and others 1987) devel-
oped an animal model to parallel the anhedonia that is
also characteristic of MDD. In rats that have experienced
a varying array of chronic mild stressors (CMS) for a 2-
week period, intake of sweetened solution is reduced
compared to nontreated animals. In this model, rats are
compared on their responses when presented with a two-
bottle choice of either normal tap water or a sweetened
water solution of either sucrose or saccharine as an
objective measure of hedonic tone. Utilization of sac-
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charine as the sweetening agent eliminates calorific
intake as a confounding factor. Additionally, rats
exposed to the CMS paradigm exhibit other behavioral
changes that parallel those in human depressives, includ-
ing decreased locomotor activity (Willner 1997) and dis-
rupted sleep (Cheeta and others 1997). The effects of
CMS can persist for several weeks after the CMS ses-
sion.
Nearly all clinically effective antidepressants tested in
this model reversed the induced reduction in consump-
tion of sweetened solution (Wilner and others 1992;
Monleon and others 1995). Moreover, sucrose prefer-
ence returned to baseline levels only after a 3- to 5-week
delay, paralleling response time to antidepressant med-
ications in those with MDD. Chronic, but not acute, anti-
depressant administration also reversed the observed
increase in 5-HT2A and beta-adrenergic receptors in the
cortex of CMS rats (Papp and others 1994a).
Furthermore, dopamine receptors were decreased in
CMS rats and this decrease was reversed by chronic
imipramine (Papp and others 1994b). Willner (1997)
reported that dopamine release is reduced in vivo in
CMS rats. Furthermore, dopamine antagonists reversed
the increase in sucrose preference elicited with antide-
pressants (Sampson and others 1991). Subsequent neu-
rophysiological analyses suggested that these effects are
mediated by dopaminergic cells in the nucleus acumbens
(Willner and others 1991).
The nucleus acumbens is thought to be a critical neu-
ral substrate for more general reward and motivational
state, appetitive behaviors, and social interaction (Wise
1998; Koob and LeMoal 2001; Nestler and others 2002).
In addition, overexpression of the transcription factor
CREB (cAMP response element binding protein) in the
nucleus acumbens is activated by stress and elicits
depressive behaviors (Pliakas and others 2001; Nestler
and others 2002). Note, however, that up-regulation of
CREB in other brain regions, most notably the hip-
pocampus, has opposite effects on depressive behavior
(Duman and others 1997).
Social Defeat
Stressful life events are important factors in the etiology
of depression. Losing a confrontation to a perceived
superior leads to low self-esteem in humans and loss of
social rank in animals and has been termed social defeat
(Marrow and others 1999). Social defeat has been pro-
posed as a natural stressor in humans (Bjorkqvist 2001),
rats (Bohus and others 1991), and mice (Koolhaas and
others 1997; Keeney and Hogg 1999). In addition to the
stress response induced by confrontational social inter-
actions, loss of rank has been associated with increased
risk of depression (Brown and others 1986). Similarly, it
is argued that in species that develop hierarchical social
structures, loss of position in these animal groups could
be considered a model of human loss of rank (Marrow
and others 1999), a situation that has been proposed as
an animal model of human depression (Willner 1995).
Social defeat in rats has been shown to induce a classic
stress response including cardiovascular and neuroen-
docrine activation, hyperthermia, and behavioral reac-
tions, such as reduced exploration in an open field test
(Meerlo, De Boer, and others 1996; Meerlo, Overkamp,
Benning, and others 1996; Meerlo, Overkamp, Daan,
and others 1996; Meerlo, Overkamp, and others 1997;
Meerlo, Pragt, and others 1997; Meerlo, Van den
Hoofdakker, and others 1997). In the Meerlo studies
(Meerlo, De Boer, and others 1996; Meerlo, Overkamp,
Benning, and others 1996; Meerlo, Overkamp, Daan,
and others 1996), the effect of the social defeat persisted
over several weeks and was reversed by total sleep dep-
rivation, consistent with sleep deprivation effects in
those with MDD (Gillin 1983; Wu and Bunney 1990)
(see Section E). The social defeat model, it has been
argued, has good construct, face, and predictive validity
(Meerlo, De Boer, and others 1996). However, more
recent studies have questioned this model on several
aspects regarding its validity (Marrow and others 1999).
The models discussed above share the common attrib-
ute of an acute stressor producing long-term behavioral
effects in adult animals that resemble the symptoms and
behavior seen in patients with MDD. However, there are
other paradigms that have stronger construct validity as
animal models of MDD, namely, those than focus on
long-term effects of early exposure and neural plasticity.
The models considered in the sections below are based
on the observation that stressful events in early child-
hood predispose one to depression later in life
(Nemeroff 1998).
Maternal Separation
Since Freud (1966) and Bowlby (1977a, 1977b), it has
been understood that the bond between mother and her
offspring has a central hold on the development of the
offspring’s emotional life. Harlow’s pioneering work
with the maternally deprived rhesus monkey repeated
this tenet (Chamove and others 1973; Ruppenthal and
others 1976). Maternally separated rhesus monkeys not
only exhibited heightened fear and aggression, and an
inability to cope with stressors, they also revealed pro-
found neuroanatomical changes (Martin and others
1991). Given these early observations and the additional
evidence that maternal separation in rats is capable of
affecting both behavioral responses and the hypothalam-
ic-pituitary-adrenal (HPA) axis response, Nemeroff’s
group (e.g., Ladd and others 1996; Heim and others
1997) has pursued the hypothesis that early maternal
separation in rats might serve as a suitable paradigm for
the effects of aversive early experience on behavioral
responsiveness to stress later in life, as an animal model
of behavioral responses associated with mood disorders
in human depressives. These workers have proposed a
stress diathesis model that postulates an interaction
between a genetic vulnerability or predisposition and
stressful life events in the genesis of human depression
(construct validity) (Ladd and others 2000). Starting
with the demonstration that maternal separation
increased adrenal responsiveness and increased novelty-
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induced fearfulness in rats, these researchers postulated
that the simple separation from the primary caregiver
could have such far-reaching effects because of two
interlinked processes—the underlying plasticity of the
developing nervous system and consequent alterations in
the regulation of the stress response (Ladd and others
2000). In support of their hypothesis, Nemeroff’s group
has demonstrated an inverse correlation between time
spent by the dam engaged in maternal behavior and sub-
sequent stress responsiveness of the offspring after
reaching adulthood (Liu and others 1997). These
researchers have also shown that several classes of anti-
depressant drugs attenuate or reverse the behavioral and
endocrinological effects of maternal separation (predic-
tive validity) (Ladd and others 1996). In addition, this
group had demonstrated that after normalization of the
behavioral and endocrine responses in the adult mater-
nal-separation-rat by antidepressant treatment, with-
drawal of the antidepressant drug treatment reverses the
positive effects of the drug, much as is seen in human
depressives after stopping their medications. This sug-
gests that the neurochemical cascade associated with
drug withdrawal is similar to the initiating events of the
primary affective episode (face validity). To test this
hypothesis, their current investigations are focused on
these behavioral and endocrinological events after with-
drawal of antidepressant drugs from adult maternal sep-
aration rats as a model for the underlying pathophysiol-
ogy of affective disorders (Ladd and others 2000).
Matthews and others (1996) used repeated separation
of rat pups from their mother during early neonatal
development. This has the effect of reducing hedonic
responsiveness as measured by the animals’ interest in
consuming sweet solutions, similar to early work using
CMS to induce anhedonia in animals.
In a paradigm that integrates maternal separation and
learned helplessness, Edwards and others (1999)
attempted to selectively breed animals susceptible to
learned helplessness and to evaluate the effect of early
stress on activity in the HPA axis. Groups of animals
were interbred for 33 generations and were subjected to
two types of stress, exposure to cold and maternal sepa-
ration. HPA activity was monitored by measuring plas-
ma corticosterone levels. As expected, corticosterone
levels increased as pups grew from day 7 to day 21 in
response to stress. The levels of corticosterone were
lower in the learned helpless group. Unstressed animals
all had similar corticosterone levels. Nevertheless, a
genetic susceptibility to developing learned helplessness
was associated with differences in the development of
HPA activity induced by stress.
Another alternative procedure for inducing depression
in animals is social isolation. Ehlers and others (1993)
used social separation to induce depressive behaviors
and found concomitant EEG activity, ACTH, and CRF.
Furthermore, these changes were different in male and
female animals, with a greater reduction in CRF recep-
tor density in males. Social isolation was also used by
Fone and others (1996) to look at physiological and
behavioral changes induced by this procedure in combi-
nation with mCPP (m-chlorophenylpiperazine), a sero-
tonin agonist. Administration of mCPP caused a greater
elevation in plasma corticosterone in animals that had
been reared in isolation than in group-housed controls.
Also, mCPP lowered levels of hippocampal 5-HT2C for
animals reared in isolation when compared to stressed
animals not receiving mCPP. The earlier results suggest
a contribution of 5-HT2C in the development of alter-
ations generated by social isolation and suggest that
these animals may show an amplified down-regulation
of 5-HT2C receptors following an agonist challenge.
Jaffe (1998) looked at Ca2+ and the effects of social iso-
lation on release of DA and 5-HT and found that extra-
cellular Ca2+ induced release of 5-HT and DA was
increased in stressed animals.
One limitation of most of the human and animal stud-
ies discussed thus far is the short duration recording
periods, particularly in those studies examining neuro-
transmitter regulation. Implicit in this work is the
assumption that brain organization and mood response is
static. There is ample evidence of diurnal variations and
rhythmic changes in mood and brain regulation. Studies
of brain regulation during sleep provide additional
insight into the role of adrenergic and cholinergic neuro-
transmitters in MDD. To evaluate the animal models of
MDD that utilize sleep EEG paradigms, we will first
consider the findings in depressed patients.
Sleep in MDD
The study of sleep EEG abnormalities in MDD has a 40-
year history, with more than 1300 published studies in
the past 20 years alone (Armitage and Hoffmann 1997),
including several seminal review articles (Reynolds and
Kupfer 1987; Knowles and MacLean 1990; Berger and
Riemann 1993). The majority of studies on macroarchi-
tecture, based on visual stage scoring of the polysomno-
gram, have reported abnormalities in the timing and/or
distribution of rapid eye movement (REM) and non-
rapid eye movement (NREM) sleep stages as primary
characteristics of those with MDD. Healthy adults typi-
cally show the first REM sleep period about 90 minutes
after sleep onset. There are usually three to five REM
periods in a given night that progressively lengthen from
a few minutes to over an hour in length. Short REM
latency (65 minutes), increased REM time, and
increased eye movement density, an index of phasic acti-
vation, have all been reported in MDD. In addition,
decreased slow-wave sleep (stages 3 and 4 of NREM);
increased awake time; early, middle, or late insomnia;
and increase light stage 1 sleep have also been reported
as characteristic of MDD (Reynolds and Kupfer 1987;
Knowles and MacLean 1990; Berger and Riemann
1993; Armitage and Hoffmann 1997). Moreover, studies
of the EEG frequencies underlying REM and NREM
sleep stages, or so-called microarchitecture, have identi-
fied additional abnormalities in those with MDD.
Increased fast-frequency beta activity and elevated alpha
has been reported in patients compared with healthy
adults (Borbély and others 1984; Armitage and others
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1992, 1993, 1995; Armitage 1995; Armitage and
Hoffmann 1997). By contrast, delta activity within
NREM sleep, also known as slow-wave activity (SWA),
is reduced in MDD (Borbély and others 1984; Kupfer
and others 1984a, 1984b, 1986, 1989). Despite clear
evidence that more than REM sleep is disturbed in
MDD, the majority of studies (including animal work)
have focused on REM.
McCarley (1982) postulated that sleep disturbances in
MDD were largely due to increased cholinergic activa-
tion that resulted in the early onset of REM sleep. This
model, based on animal studies (Hobson and others
1975; McCarley and Hobson 1975), assumes that
because cholinergic neurons in the pontine reticular for-
mation of the brain stem are activated during REM sleep
whereas noradrenergic/serotonergic neurons in the locus
coeruleus and dorsal raphe are deactivated, the neuro-
transmitter systems involved in REM sleep control are
reciprocal and responsible, in part, for subsequent
REM/NREM sleep cycle oscillations. He reasoned that
an early onset of REM sleep in MDD (i.e., short REM
latency) reflects an imbalance in normal cholinergic/
aminergic neurotransmission that produces disinhibition
of REM sleep (McCarley 1982; Massaquoi and
McCarley 1992; McCarley and Massaquoi 1992). There
has been fairly strong support that the administration of
cholinergic agonists indeed triggers an earlier onset of
REM in both animal and human studies (cf. Riemann
and Berger 1992; Riemann and others 1992; Riemann,
Hohagen, Krieger, and others 1994; Riemann, Hohagen,
Bahro, and Berger 1994; Riemann, Hohagen, Bahro,
Lis, and others 1994), although the response has not
always been largest in those with MDD (Berger and oth-
ers 1989; Gillin and others 1991). Nevertheless, most
studies have shown a shorter mean REM latency or
inter-REM-interval in response to cholinergic challenge
in those with MDD, compared with healthy controls,
including very recent work on orally administered ari-
cept (Perlis and others 2002).
Antidepressant Effects on REM Sleep
Most antidepressants suppress REM sleep, either
increasing the latency to the first REM sleep period or
decreasing total REM sleep time (for a review, see Vogel,
Buffenstein, and others 1990; Sharpley and Cowen
1995; Thase 1998; Armitage 2000). MAOIs are the most
potent REM suppressors, even eliminating REM sleep in
some patients, although this may not be the case with
newer reversible MAOIs (Monti 1989; Minot and others
1993). With the exception of iprindole and trimipramine,
TCAs are also potent REM suppressors, with the largest
effects observed for clomipramine and desipramine
(Dunleavy and others 1972; Kupfer and others 1989,
1991). Moreover, clinical response to some TCAs
(clomipramine and amitriptyline) appears tied to the
degree of REM sleep suppression (Kupfer and others
1976; Gillin and others 1978; Hochli and others 1986).
These findings were also consistent with the clinical
response obtained with behavioral REM sleep depriva-
tion, achieved by awakening patients every time they
showed electrophysiological characteristics of REM
sleep (Vogel and others 1968). This, coupled with the
view that REM sleep was increased in patients with
depression, led Vogel and colleagues to postulate that the
antidepressant response to pharmacological agents was
due to the REM suppressing effects (Vogel, Buffenstein,
and others 1990). However, more recent studies have
demonstrated that improvement in depressive symptoms
on SRIs is not correlated with the induced REM sleep
changes (van Bemmel, Beersma, and others 1993; van
Bemmel, Van den Hoofdakker, and others 1993; Staner
and others 1995; Rush and others 1998). Moreover, there
are a number of antidepressant agents that are clinically
efficacious but do not suppress REM sleep, including
nefazodone (Armitage and others 1997; Rush and others
1998), bupropion (Nofzinger and others 1995), and
mianserin (Mendlewicz and others 1985). Nevertheless,
the suggestion that REM sleep plays a unique role in
depressive symptomatology and behavior has persisted
and has strongly influenced animal models of MDD.
Animal Models of REM Sleep 
Abnormalities in MDD
REM Deprivation and Antidepressants
in Neonatal Rats
In the early 1980s, Mirmiran, Corner, and their cowork-
ers (Corner and others 1980; Mirmiran and others 1983;
Mirmiran 1986) began testing the hypothesis, originally
proposed by Roffwarg and others (1966), that the abun-
dance of REM sleep observed in developing organisms
serves an active and necessary function in the normal
development of the CNS. Mirmiran and others (Corner
and others 1980; Mirmiran and others 1981, 1983;
Mirmiran 1986) adopted a lesion paradigm to test this
hypothesis and eliminated REM sleep in neonatal rats by
daily injections of an antidepressant drug, which sup-
presses REM sleep. Daily clomipramine (CMI) injec-
tions or saline injections were continued from 8 days to
21 days postnatal. As adults, the two treatment groups
were tested on sexual response, aggression, open field
behavior, and several measures of brain development as
well as a number of standard sleep stage indices.
Compared with controls, CMI-treated males exhibited
maturational deficiencies on the behavioral measures,
REM sleep alterations, and reduced sizes of specific
anatomical brain measures. Mirmiran was equivocal
with regard to attributing these deficiencies to increased
5-HT2 or reduced neural activation (Mirmiran 1986).
Soon after, however, Vogel (Vogel and others 1980)
observed that the behavioral abnormalities exhibited by
Mirmiran and others’s REM sleep-deprived rats closely
paralleled certain features of behavior of some of his
human MDD patients. He subsequently initiated studies
assessing this model as a pharmacologically induced
model of MDD (Vogel, Neill, Kors, and others 1990;
Yavari and others 1993). The rats’ open field and sexual
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behavior is “depressed” compared with normals. They
show decreased sexual, aggressive, reduced reward-
seeking in the form of intracranial self-stimulation activ-
ity, and hyperactivity in the outer areas of the open field
tests (face validity). Even more convincing perhaps was
Vogel’s finding that CMI-treated rats have disordered
REM sleep patterns as adults that resemble those found
in some patients with MDD (Vogel, Neill, Kors, and oth-
ers 1990), for example, increased REM sleep amounts,
an increased number of sleep-onset REM periods, and
decreased REM sleep latency. Furthermore, Vogel, Neill,
Hagler, and others (1990) reported that some of the neg-
ative behavioral effects of early CMI treatment can be
improved in these animals by administration of
imipramine (predictive validity).
The interpretation of these observations, however, is
less than straightforward. In particular, the construct
validity of the use of systemic CMI injections remains
uncertain. Neonatal treatment of rats with systemic
injections of this powerful monoamine reuptake blocker,
which is relatively selective for serotonin (5-HT), may
have nonspecific effects in the developing CNS aside
from those directly affecting the brain regions thought to
mediate MDD. This would be particularly true for a
compound like CMI, which so strongly affects the whole
of the monoaminergic system that is diversely and wide-
ly represented in the brain and most active during wak-
ing. Accordingly, the systemic injections utilized in the
Vogel/Mirmiran model may affect CNS development in
ways that are unrelated to the effect on the role REM
sleep plays in brain maturation, normal or otherwise. It
is perhaps procedurally more defensible to specifically
eliminate REM sleep during development by instrumen-
tally removing REM sleep without drugs. By making
more circumscribed “lesions” with such instrumental
means to cause behavioral and REM-sleep alterations in
adult rats, which accurately parallel the human condi-
tion, it is possible to produce a model of MDD with
stronger construct validity.
REM Deprivation in Neonatal Rats Utilizing
Instrumental Techniques
As mentioned above, consumption of saccharine solu-
tion has been utilized in rats as a test of hedonic tone
(Willner 1997). Preliminary studies in rats that were
REM deprived (or not) when young, utilizing instru-
mental methods (Hogan and others 2001), demonstrated
differences in preference for saccharine water over tap
water when the rats were adults > 60 days postnatal. The
animals presented in Figure 3 were at least 60 days post-
natal when tested and were REM deprived between days
21 and 28 postnatal.
The rats were REM-deprived by a mechanism that
shook their cage whenever the computer detected an
entrance to the REM sleep based on amplitude criteria
applied to the digitized ECoG and EMG signals (Hogan
and others 2001). Littermate controls were stimulated on
a regular “make-up” schedule that delivered the same
number of shakes as its “yoked” REM-deprived rat had
received in the preceding half hour. Thus, both groups
received the same number of shakes, but the control rats
Fig. 3. Rats between the ages of P21 and P28 are REM sleep-deprived (REMSD) by a mechanism that shook their cages whenever
the computer detected an entrance to the REM sleep state on the digitized electrophysiology. Littermate controls were stimulated on
a regular “make-up” schedule that delivered the same number of shakes as its “yoked” REMSD rat had received in the preceding half
hour. Thus, both groups received the same number of shakes, but the control rats received most of their shakes while awake only.
After this phase and prior to the behavioral testing, which began at P90, REMS deprived and control animals are kept in standard mul-
tianimal housing and on standard lighting schedules (12L/12D). During the saccharine test, the rats are kept in standard housing but
are deprived of fluids for 23 hours. At the end of each 23-hour period, animals are removed to individual cages that have two water
bottles, which are randomized on a day-to-day basis for position. One bottle is tap water and the other is a variable concentration tap
water and saccharine solution. Animals are given free access to choose between either tap water or a varying concentration saccha-
rine solution for one hour daily. Tested as adults, REMSD rats consumed similar amounts of water to either the yoked shaker control
animals or the controls reared in their home cage. The latter consumed more saccharine solution than either REMSD or shaker con-
trol animals. Although the REMSD animals consumed less saccharine solution than the home cage controls, it is of interest that the
yoked shaker control animals showed a larger experimental effect on saccharine consumption. It is conceivable that the cage-shak-
ing stimulation may be a stronger stressor to the shaker control group by virtue of its presentation in wakefulness compared with that
used to eliminate REMS in the REMSD group.
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received most of their shakes while awake only. After
this phase and prior to the behavioral testing at > 60 days
postnatal, REM-deprived and control animals were kept
in standard multi-animal housing and on standard light-
ing schedules (12L/12D). Tested as adults, the REM-
deprived rats consumed similar amounts of water to
either the yoked control animals on the shakers or the
home cage–reared controls. The latter consumed more
saccharine solution than either REM-deprived or shaker
control animals. Although the REM-deprived animals
consumed less saccharine solution than the home cage
controls, it is of interest that the yoked shaker control
animals showed a larger effect of treatment on saccha-
rine consumption. It is conceivable that the cage-shaking
stimulation may be a stronger stressor for the control
animals than that used for the REM-deprived experi-
mental group, as the controls receive the stimulation in
wakefulness rather than during REM sleep. It has been
argued that all forms of sleep deprivation are stressful
(Rampin and others 1991); however, the stimulation of
the shaker control group, given the present results, sug-
gests that this condition is similar to the Willner (1997)
condition of chronic mild stress. Presentation of the
stressor early in life during the neonatal plasticity period
may allow for the effectiveness of the treatment over the
relatively short period of these experiments.
These results have ramifications for the present con-
sideration of animal models of MDD. It could be argued
that both varieties of this REM deprivation model pos-
sess some face validity. Both reduce hedonic tone in
adult animals after a stressful treatment during the
neonatal plasticity phase. Likewise, both models have
some construct validity, and though it remains to be con-
firmed for the instrumental REM deprivation version, if
it too follows the Vogel data, both versions could also
have predictive validity. The instrumental REM depriva-
tion model might be particularly useful for comparisons
with chronic mild stress models, given they are produced
in the same species at different points in the animal’s
life: in early development with the former and in the
adult with the latter.
The Flinders Sensitive Line of Rats
Depressive disorders in humans are well known to have
a genetic component. However, only relatively recently
have models been put forth that have a genetic basis. The
Flinders Sensitive Line (FSL) of rats (so called because
the line was first bred at the University of Flinders,
Australia) is one of the earliest (Overstreet and Russell
1982; Russell and others 1982; Overstreet 1986) and
best studied line of animals specifically bred as a genet-
ic animal model of depression (for a review, see
Overstreet 1993; Overstreet and others 1995; Yadid and
others 2000). Based on the observation that human
depressives are supersensitive to cholinergic agonists
(Janowsky and others 1980), the original FSL rats were
developed by selective breeding for high and low sensi-
tivity (Flinders Resistive Line [FRL]) to the anti-
cholinesterase, diisopropyl fluorophosphate. After deter-
mining that the differences between the FSL and FRL
rats were not due to bred-in changes in acetyl-
cholinesterase, the line was eventually standardized to
the animal’s hypothermic response to a specific dose of
the muscarinic agonist, oxotremorine (Overstreet and
Russell 1982; Russell and others 1982). In addition to
the indicated construct validity, there are many behav-
ioral similarities between the FSL rats and their
depressed human counterparts (Overstreet 1993;
Overstreet and others 1995; Yadid and others 2000).
Besides being more sensitive to cholinergic agonists, the
FSL rats have elevated REM sleep (Shiromani and oth-
ers 1988), appetite and weight changes (Overstreet
1993), reduced activity (Overstreet and Russell 1982;
Russell and others 1982), an increased anhedonia after
exposure to CMS (Pucilowski and others 1993), and
exaggerated immobility in the Porsolt forced swim test
(Overstreet and others 1994; Overstreet 1986). Several
physiological similarities between human depressives
and FSL rats add to the face validity of the model.
Patients with MDD have been shown to have HPA axis
dysfunction, abnormalities in both slow-wave and REM
sleep, and immune dysfunctions. All these are reflected
in the physiology of their FSL counterpart (Overstreet
1993). In terms of REM sleep, FSL rats have a greater
amount of REM and a shorter interval between REM
sleep periods. FSL rats do not exhibit the large decreas-
es in slow-wave sleep that have been reported in
depressed humans, leading to the suggestion that sleep
alterations are related to circadian rhythm abnormalities
in FSL rats. This notion is not inconsistent with a phase
advance of a circadian oscillator hypothesized as a char-
acteristic of MDD (Czeisler and others 1987). To date,
however, the evidence in those with MDD does not sup-
port an advance in circadian phase (Monk and others
1994). Although the FSL do not entirely mimic the HPA
abnormalities seen in depressed humans, on many meas-
ures, the model does have high construct and face validity.
A large body of data addresses the predictive validity
of the FSL based on the effects of a variety of antide-
pressant treatments. The predictive validity of the FSL
model of depression has been most often demonstrated
using the Porsolt (Porsolt and others 1978) forced swim
test, utilizing the length of time spent floating immobile
in a cylinder of water as the dependent measure.
Typically applied in normal rats as a screen for antide-
pressant activity of candidate drugs, in this case the rat
is subacutely administered the antidepressant between
two sessions in the swim tank spaced 24 hours apart.
Because FSL rats are more immobile than normals, the
preliminary session in the swim tank was eliminated and
the putative antidepressant was given chronically for 14
days prior to the test in the swim tank. Data indicate that
the FSL rats exhibited positive, antidepressant-like
responses in the swim test when treated chronically with
classical tricyclics, imipramine and desipramine, or the
newer generation antidepressants, SRIs, like sertraline
and paroxetine (Overstreet 1993; Yadid and others
2000). Because chronic treatment with accepted antide-
pressants, but not with a variety of other agents, reduces
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the immobility of FSL rats, the model has a high degree
of predictive validity (Pucilowski and Overstreet 1993;
Overstreet and others 1995; Yadid and others 2000). It
has been proposed that the pattern of drug effects in this
model indicates the possibility of serotonergic mecha-
nisms controlling the exaggeration of the immobility of
the FSL rats and argues against a direct role for cholin-
ergic mechanisms in the exaggerated immobility
(Overstreet and others 1995). Recent data have broad-
ened the applicability of the FSL model from the tradi-
tional monoaminergic models to include neuromodula-
tors, such as beta-endorphin (Yadid and others 2000) and
other neurotransmitters/neuromodulators, for example,
GABA, several neuropeptides, and growth factors that
broaden the perspective well beyond REM sleep (Nestler
1998). From our viewpoint, NREM sleep abnormalities
are of equivalent importance in understanding the neu-
robiology of MDD.
NREM Sleep in MDD
Rather than increased REM activation or REM sleep dis-
inhibition, Borbély and colleagues suggested that
NREM sleep regulation and homeostasis are impaired in
those with MDD (Borbély and Wirz-Justice 1982). This
hypothesis is based on a two-process model of sleep reg-
ulation (Borbély 1982a, 1982b), where the amount of
SWA in NREM sleep is determined by the amount of
prior wakefulness, the level of sleep propensity during
the day, and depth of sleep at night (Process S). Process
S accumulates during waking hours and slow-wave sleep
propensity rises and dissipates over the night as the SWA
declines. Measuring the temporal SWA evolution during
NREM sleep is presumed to approximate Process S, and
thus there is an exponential decline in SWA across suc-
cessive NREM sleep periods. The second process
(Process C) reflects the circadian control of sleep
propensity that is highest at 3 to 5 a.m., when it is very
difficult to overcome the need to sleep, and is lowest at
4 p.m., when sleep propensity is minimal. Process C is
presumed to reflect internal clock control of circadian
rhythms, the threshold for maintaining wakefulness and
REM sleep control, and is unaffected by the amount of
prior wakefulness. It is assumed that in a healthy brain,
the propensity for REM sleep increases as SWA dissi-
pates, thus explaining the short-duration first REM peri-
od when SWA pressure is high, and the increase in REM
as SWA dissipates across the night (Borbély 1982a,
1982b). Thus, the time course of SWA approximates
Process S, not the total amount of SWA.
With regard to MDD, Borbély and Wirz-Justice
(1982) proposed that the reduction in slow-wave sleep
reported in some patients with MDD resulted from an
impairment in Process S, with diminished accumulation
of sleep pressure during the daytime and reduced dissi-
pation of SWA at night. Thus, both slow-wave sleep time
and SWA are reduced in the initial NREM sleep period,
allowing an earlier onset of the first REM period with a
longer duration. In a later review article, Wirz-Justice
(1995) further postulated that extending prior wakeful-
ness or sleep deprivation would normalize SWA regula-
tion and Process S in MDD. Note, however, that the only
evidence cited in support of the proposed Process S defi-
ciency in MDD were the antidepressant effects of sleep
deprivation and relapse after recovery sleep and reduced
slow-wave sleep time coupled with short REM (Borbély
and Wirz-Justice 1982).
As mentioned above, reduced SWA has also been
reported as a characteristic of MDD (Borbély and others
1984; Armitage and others 1992, 1993, 1995; Armitage
1995; Armitage and Hoffmann 1997). Moreover,
Kupfer’s group reported on the abnormal distribution of
SWA in those with MDD (Kupfer and others 1990). Our
own work has shown that the time course of SWA is
abnormal in those with MDD (Armitage, Hoffmann,
Fitch, and others 2000; Armitage, Hoffmann, Trivedi,
and others 2000) but adds the caveat that it appears to be
sex dependent. Men with MDD had a significantly slow-
er rate of decay with lower initial accumulation of SWA
than all other groups. These SWA abnormalities appear
to be specific to MDD and were not evident in men with
schizophrenia (Hoffmann and others 2000). It should be
noted that a definitive study of homeostatic abnormali-
ties in MDD requires a direct manipulation of SWA
through sleep deprivation. Nevertheless, these data pro-
vide strong evidence of sex differences in sleep EEG in
those with MDD. Moreover, women with MDD are more
likely to show dysregulation and loss of synchronized
ultradian sleep EEG rhythms (cf. Armitage and others
1999; Armitage and Hoffmann 2001). Although both
men and women are vulnerable to the disease, it appears
that females are inherently at greater risk for MDD. Sex
steroids no doubt play a major role. Coupled with
reports of sex differences in the symptoms of MDD
(Shaw and others 1995) response to antidepressant treat-
ment (Thase and others 2000) and lifetime risk for MDD
(Kessler 2000), these findings suggest that the underly-
ing pathophysiology of MDD is also gender dependent.
Gender, Sex Steroids, and MDD
Several lines of evidence suggest that the sex differences
in prevalence and pathophysiology of MDD relate to sex
steroids and hormonal regulation. First, women are at
twice the lifetime risk for MDD during the reproductive
years from puberty to menopause (Kessler 2000).
Postpartum (Garvey and Tollefson 1984) and premen-
strual periods (Rausch and Parry 1993) and the use of
high-progesterone oral contraceptives (Cullberg 1972)
all increase the risk of dysphoria and mood disturbance
(Janowsky and others 1996; Parry 2000). As suggested
by the animal studies reviewed above, serotonin, cate-
cholamines, GABA, and acetylcholine all play a role in
depressive behaviors. Serotonin is also implicated in the
regulation of gonadotropin release, particularly in neu-
rons in the dorsal raphe and neurons in the preoptic area
that release luteinizing hormones (Tanaka and others
1993; Tillet and others 1993). Sensitivity to tryptophan
and resultant behavior effects of depletion may also be
sex dependent in rats and mice and in humans (Matsuda
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and others 1991; Marsh and others 2002). Moreover,
gonadectomy and chronic steroid exposure alter
monoaminergic metabolism (Bitar and others 1991).
Estrogen or estradiol also has direct effects on serotonin
receptor availability, and tryptophan levels have been
shown to be associated with postpartum depression
(Rausch and Parry 1993). Ovarian steroids probably also
influence the synthesis release and metabolism of cate-
cholamines, as reviewed by Janowsky and others (1971).
Estrogen also alters alpha 2 adrenergic binding in
platelets, depending on the phase of the menstrual cycle
in humans (Best and others 1992). Both GABAA and
GABAB receptor complexes are directly influenced by
sex steroids, although the effects are region specific and
opposite for estrogen and progesterone (Schumacher and
others 1989).
Perhaps most striking, the expression of the regulation
of progesterone and estrogen is sex dependent. Thus, sex
differences are even evident on the molecular levels
(Pfaff and Severino 1996). There is overwhelming evi-
dence of sexual dimorphism in brain structure and func-
tion, most notably cerebral-evoked potentials, cerebral
glucose metabolism and blood flow, overall metabolic
rates, and hypothalamic pituitary adrenal axis response
to challenge (Gur and Gur 1990; Allen and others 1991;
Gur and others 1995; Manber and Armitage 1999;
Rhodes and Rubin 1999). This, coupled with the impact
of ovarian steroids on brain regulation, is suggestive of
greater adaptive response or neural plasticity in females.
Indeed, there is evidence from sleep studies to support
this view. Healthy young females appear to show a
greater SWA response to sleep deprivation than healthy
young males (Armitage and others 2001). Such findings
not only indicate a greater response to challenge in gen-
eral, but specifically to a homeostatic challenge and may
well reflect greater neuronal plasticity.
We have argued that the sex differences in brain
organization give rise to sex-specific vulnerabilities to
brain dysregulation under conditions of extreme chal-
lenge. Thus, greater plasticity should produce hyperre-
sponsivity, whereas more static brain organization would
be more likely to move toward inertia.
Recent preliminary data have shown that women with
MDD show an even greater SWA response to homeosta-
tic challenge than healthy control women. By contrast,
men with MDD show little SWA response to sleep dep-
rivation. Thus, the women with MDD appear hyperre-
sponsive, whereas the men with MDD are hyporespon-
sive (Fig. 4).
The view that homeostatic abnormalities contribute to
MDD is also supported by the work of Duman and col-
leagues (Duman 1999). Their view is that receptor regu-
lation and adaptation to changes in monoamine levels
serves to maintain homeostasis. They also suggest that
stress exposure results in neural atrophy or damage. The
mechanisms generating SWA and sleep regulation may
be of critical importance to understanding sex differ-
ences in MDD. Neurotrophic factors, atrophy, and cell
damage could reduce SWA and impair homeostatic reg-
ulation. Neuronal damage could then lead to increased
sensitivity to stress and impair HPA regulation and feed-
back to other brain areas (Duman 1999). Postmortem
studies of suicide victims are consistent with this view
(Mann and Arango 1999). The neurotrophic hypothesis
of MDD is consistent with our data in men but requires
some revision to account for the findings in women. This
is also true for the animal studies reviewed.
Remarkably, sex differences in sleep homeostasis are
even evident in Drosophila lacking the circadian cycle
(cyc01) gene. Shaw and colleagues (2002) reported a 3
times greater recovery from sleep deprivation in cyc01
females than males. These data provide strong support
for sexual dimorphism in fundamental brain regulation
and circadian rhythm homeostasis under high-stress con-
ditions and lay credence to our suggestion that this sex-
ual dimorphism contributes to genesis of depression.
The idea of greater neural plasticity in females has
relevance well beyond depression. Studies of neural
degeneration, Alzheimer’s disease, recovery from stroke,
and normal aging all indicate more plastic brain organi-
zation in females. Moreover, there are numerous instinc-
tive behaviors necessary for survival that are sexually
dimorphic, reproductive behavior in particular. We spec-
ulate that most if not all appetitive behaviors, sleep reg-
ulation included, are sexually dimorphic. We suggest
that the genesis of MDD is related to homeostatic mal-
adaptation that is sex specific.
If our speculations are correct, similar sex differences














Fig. 4. The Effects of a 2-hour sleep delay on the accumulation
of slow-wave activity (SWA) by group and sex: SWA is derived
from power spectral analysis in the 0.5-4 Hz frequency band
(left central electrode) in the first non-rapid eye movement
(NREM) (stages 2, 3, and 4) period, expressed relative to aver-
age SWA in all NREM sleep time in major depressive disorder
(MDD) women (MDDW) and MDD men (MDDM) compared with
age-matched healthy normal control women (NCW) and men
(NCM). SWA data are shown for baseline sleep and after a 2-
hour delay of habitual bedtime. Prior wakefulness is held con-
stant within and across groups. Note the lower accumulation of
SWA in the depressed men, both at baseline and after the delay,
evidence of homeostatic hyporesponse. All other groups
showed higher percentage SWA in response to delay, with the
largest response in MDD women, evidence of homeostatic
hyperresponse. Also note that the magnitude of the sex differ-
ence is twice as large in the group with MDD as evidenced by a
significant group-by-sex interaction (P < 0.03). Armitage and
others (2002).
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predict that maternal separation, sleep deprivation, and
chronic stress should all produce larger effects in female
animals. Alternatively, greater neural plasticity and
adaptive response in females may result in a faster recov-
ery or may depend on the timing of exposure.
Establishing potential sex differences in critical periods
of brain development and vulnerability to environmental
stressors is essential to understanding the neurobiology
of MDD and relative risk for this disease.
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